- Home
- MRKR vs OCEA Comparison
MRKR vs OCEA Comparison
Compare MRKR & OCEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- OCEA
- Stock Information
- Founded
- MRKR N/A
- OCEA 2019
- Country
- MRKR United States
- OCEA United States
- Employees
- MRKR N/A
- OCEA N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- OCEA Biotechnology: Pharmaceutical Preparations
- Sector
- MRKR Health Care
- OCEA Health Care
- Exchange
- MRKR Nasdaq
- OCEA Nasdaq
- Market Cap
- MRKR 21.9M
- OCEA 20.5M
- IPO Year
- MRKR N/A
- OCEA N/A
- Fundamental
- Price
- MRKR $2.16
- OCEA $0.47
- Analyst Decision
- MRKR Strong Buy
- OCEA
- Analyst Count
- MRKR 1
- OCEA 0
- Target Price
- MRKR $19.00
- OCEA N/A
- AVG Volume (30 Days)
- MRKR 53.9K
- OCEA 631.6K
- Earning Date
- MRKR 11-14-2024
- OCEA 01-13-2025
- Dividend Yield
- MRKR N/A
- OCEA N/A
- EPS Growth
- MRKR N/A
- OCEA N/A
- EPS
- MRKR N/A
- OCEA N/A
- Revenue
- MRKR $5,395,849.00
- OCEA N/A
- Revenue This Year
- MRKR $64.48
- OCEA N/A
- Revenue Next Year
- MRKR N/A
- OCEA N/A
- P/E Ratio
- MRKR N/A
- OCEA N/A
- Revenue Growth
- MRKR 79.04
- OCEA N/A
- 52 Week Low
- MRKR $1.83
- OCEA $0.43
- 52 Week High
- MRKR $5.99
- OCEA $7.79
- Technical
- Relative Strength Index (RSI)
- MRKR 32.84
- OCEA 34.89
- Support Level
- MRKR $1.83
- OCEA $0.53
- Resistance Level
- MRKR $2.79
- OCEA $0.70
- Average True Range (ATR)
- MRKR 0.28
- OCEA 0.08
- MACD
- MRKR -0.09
- OCEA -0.02
- Stochastic Oscillator
- MRKR 21.02
- OCEA 10.28
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
About OCEA Ocean Biomedical Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.